First Trust Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

First Trust Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-26,784	Closed	-$3.9M	–	2683
2022 Q2	$3.9M	Sell	26,784 -14,436	-35%	-$1.84M	﹤0.01%	1391
2022 Q1	$4.89M	Sell	41,220 -13,385	-25%	-$1.67M	0.01%	1335
2021 Q4	$7.53M	Sell	54,605 -37,642	-41%	-$4.79M	0.01%	1176
2021 Q3	$12.8M	Buy	92,247 +58,707	+175%	+$7.33M	0.01%	933
2021 Q2	$3.26M	Buy	+33,540	New	+$2.72M	﹤0.01%	1617
2021 Q1	–	Sell	-46,827	Closed	-$4.01M	–	2513
2020 Q4	$4.01M	Sell	46,827 -9,666	-17%	-$819K	0.01%	1191
2020 Q3	$3.67M	Buy	56,493 +4,648	+9%	+$305K	0.01%	1081
2020 Q2	$3.79M	Buy	+51,845	New	+$2.76M	0.01%	1092

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

First Trust Advisors's BHVN Position: Q3 2022 in Review

First Trust Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 26,784 shares — an estimated $3.9M sold.

First Trust Advisors first reported a position in BHVN in Q2 2020 and held it in 8 quarters. The position peaked at $12.8M in Q3 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

First Trust Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
First Trust Advisors sold 26,784 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $3.9M.
First Trust Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 8 quarters.
First Trust Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $12.8M in Q3 2021.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on First Trust Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.